PharmaCyte Biotech (PMCB) Acquisitions (2011 - 2013)

PharmaCyte Biotech (PMCB) posted quarterly Acquisitions of -$1.5 million for Q4 2013, down 196.74% quarter-over-quarter from $1.6 million in Q3 2013.

PharmaCyte Biotech (PMCB) Acquisitions (2011 - 2013) Analysis & Trends

PharmaCyte Biotech (PMCB) has reported Acquisitions for 3 consecutive years, with -$1.5 million the latest figure, recorded in Q4 2013.

In Q4 2013, Acquisitions changed N/A year-over-year to -$1.5 million; the TTM figure through Jul 2014 stood at -$1.5 million (down 234.65% YoY), while the FY2014 annual figure was $51215.0, changed N/A from the prior year.
Acquisitions slipped to -$1.5 million in Q4 2013 per PMCB's latest filing, from $1.6 million in the prior quarter.
Across five years, Acquisitions topped out at $1.6 million in Q3 2013 and bottomed at -$1.5 million in Q4 2013.
Historically, Acquisitions has averaged -$135790.7 across 3 years, with a median of -$240000.0 in 2011.
On a YoY basis, Acquisitions climbed as much as 233.33% in 2013 and fell as far as 233.33% in 2013.
PharmaCyte Biotech's Acquisitions stood at -$240000.0 in 2011, then jumped by 50.0% to -$120000.0 in 2012, then plunged by 1164.7% to -$1.5 million in 2013.
Business Quant data shows PMCB's Acquisitions at -$1.5 million in Q4 2013, $1.6 million in Q3 2013, and -$481750.0 in Q2 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	139.82 Bn	131.97 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	86.70 Bn	78.71 Bn	3.93 Bn	-
3	Argenx Se	65.27 Bn	60.09 Bn	1.37 Bn	-
4	Moderna	59.18 Bn	54.04 Bn	52.00 Mn	-
5	BeOne Medicines	42.11 Bn	37.01 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn	-
7	BioNTech SE	28.14 Bn	9.75 Bn	668.28 Mn	-
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	-
9	Royalty Pharma	27.26 Bn	26.42 Bn	-	-
10	PharmaCyte Biotech	4.44 Mn	4.44 Mn	-	-

Download Data